MARKSANS vs VENUSREM: Stock Comparison
MARKSANS PHARMA is the larger company by market capitalisation. MARKSANS PHARMA shows a higher ROE, a higher ROCE and a higher net margin, while VENUSREM shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MARKSANS leads 4; VENUSREM leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Live Price | ₹294.45 | ₹1,796.7 |
| Day Change | -1.24% | 0.03% |
| Volume | 8.18 L | 1.17 L |
| 52-Week High | ₹350.95 | ₹1,880 |
| 52-Week Low | ₹155 | ₹432.1 |
| Distance from 52W High | -16.1% | -4.43% |
Valuation
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Market Cap | ₹13,595 Cr | ₹1,924 Cr |
| P/E Ratio | 26.32x | 16.56x |
| P/B Ratio | 4.5x | 2.9x |
| EPS | ₹3.47 | ₹17.18 |
| Book Value | ₹67.36 | ₹496.56 |
| Dividend Yield | 0.3% | 0.66% |
Growth
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.8% | 33% |
| EPS Growth (TTM YoY) | 63.5% | 126.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| ROE | 18.2% | 15.49% |
| ROCE | 19.33% | 16.2% |
| Net Margin | 14.16% | 13.35% |
| Operating Margin | 29.29% | 17.56% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Promoter Holding | 43.87% | 41.76% |
| FII Holding | 19.06%▲ 1.59 pp | 3.14%▲ 0.22 pp |
| DII Holding | 5.54%▼ 0.65 pp | 0.74%▼ 0.15 pp |
| Public Holding | 31.53%▼ 0.94 pp | 54.36%▼ 0.07 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MARKSANS PHARMA and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.